[Current Data] Rule running report - 2024-02-28 15:48:32.380332

Nr2MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase… succesfully run! 0 Anläufe!